Journal of Vascular and Interventional Radiology
Volume 21, Issue 2 , Pages 175-177 , February 2010

Statin Prescription is Essential in Peripheral Vascular Disease

  • Joe J. Leyon, MBBS, MRCP

      Affiliations

    • Department of Radiology, Sandwell and West Birmingham Hospitals National Health Service Trust, Lyndon, West Bromwich, West Midlands B71 4HJ, UK
    • Corresponding Author InformationAddress correspondence to J.J.L.
    • ,
  • Saraswathy Jaiveer, MBBS, MRCP

      Affiliations

    • Department of Radiology, United Lincolnshire Hospitals National Health Service Trust, Lincolnshire, United Kingdom
    • ,
  • Derek L. Connolly, BSc (Hons), MBChB(Edin), PhD, FRCP

      Affiliations

    • Department of Cardiology, Sandwell and West Birmingham Hospitals National Health Service Trust, Lyndon, West Bromwich, West Midlands B71 4HJ, UK
    • ,
  • Suresh Babu, MBBS, DMRD, FRCP, FRCR

      Affiliations

    • Department of Radiology, Sandwell and West Birmingham Hospitals National Health Service Trust, Lyndon, West Bromwich, West Midlands B71 4HJ, UK

Received 1 November 2009 ,Revised 9 November 2009 ,Accepted 9 December 2009.

References 

  1. Gottsäter A. Managing risk factors for atherosclerosis in critical limb ischaemia. Eur J Vasc Endovasc Surg. 2006;32:478–483
  2. Laws PE, Spark JI, Cowled PA, Fitridge RA. The role of statins in vascular disease. Eur J Vasc Endovasc Surg. 2004;27:6–16
  3. Pedersen TR, Kjekshus J, Pyörälä K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1998;81:333–335
  4. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45:645–654
  5. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg. 2009;38:463–474
  6. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207
  7. Institute for Clinical Systems Improvement. ICSI Health Care Guideline: Lipid Management in Adults. Bloomington, MN: ICSI; 2009;http://www.icsi.org/guidelines_and_more/gl_os_prot/cardiovascular/lipid_management_3/lipid_management_in_adults__4.htmlAccessed November 9, 2009
  8. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239
  9. Smith SC, Allen J, Blair SN, et al. AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006;47:2130–2139

 None of the authors have identified a conflict of interest.

PII: S1051-0443(09)01542-5

doi: 10.1016/j.jvir.2009.12.381

Journal of Vascular and Interventional Radiology
Volume 21, Issue 2 , Pages 175-177 , February 2010

Article Tools

* Image Usage & Resolution